Research article

              Phenothiazines induce PP2A-mediated
                    apoptosis T cell acute
                     lymphoblastic leukemia
     Alejandro Gutierrez,1,2 Li Pan,3 Richard W.J. Groen,4,5 Frederic Baleydier,3,6 Alex Kentsis,1,2
    Jason Marineau,4 Ruta Grebliunaite,1 Elena Kozakewich,1 Casie Reed,1 Francoise Pflumio,7,8
  Sandrine Poglio,7,8 Benjamin Uzan,7,8 Paul Clemons,9 Lynn VerPlank,9 Frank 9 Jason Burbank,9
        Stephanie Norton,9 Nicola Tolliday,9 Hanno Steen,10 Andrew P. Weng,11 Huipin Yuan,12
          James E. Bradner,4 Constantine Mitsiades,4  Thomas Look,1,2 Jon C. Aster3
                  1Department Pediatric Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA.
       2Division
               Hematology/Oncology, Boston Childrenâ€™s Hospital Harvard Medical School, Boston, Massachusetts, USA. 3Department Pathology,
                 Brigham Womenâ€™s Hospital Harvard Medical School, Boston, Massachusetts, USA. 4Department Medical Oncology,
   Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA. 5Department Cell Biology, University Medical Center Utrecht,
                            Utrecht, Netherlands. 6Department Pediatric Hematology, Hospices Civils Lyon, Lyon, France.
           7Laboratoire Recherche sur les Cellules Souches HÃ©matopoÃ¯Ã©tiques et LeucÃ©miques, Institut Radiobiologie Cellulaire et MolÃ©culaire,

  Direction des Sciences du Vivant, Commissariat Ã  lâ€™Energie Atomique et aux Energies Alternatives, Institut National la SantÃ© et la Recherche MÃ©dicale,
             Fontenay-aux-Roses UniversitÃ© Paris-Sud, Fontenay-aux-Roses, France. 8UniversitÃ© Paris-Diderot, Paris, France. 9Broad Institute,
         Cambridge, Massachusetts, USA. 10Proteomics Center Department Pathology, Boston Childrenâ€™s Hospital Harvard Medical School,
          Boston, Massachusetts, USA. 11British Columbia Cancer Agency, Vancouver, Canada. 12Xpand Biotechnology BV, Bilthoven, Netherlands.



    T cell acute lymphoblastic leukemia (T  aggressive cancer frequently associated activating
    mutations NOTCH1 dysregulation MYC.  performed 2 complementary screens identify
    FDA-approved drugs drug-like small molecules activity T  developed zebrafish
    screen small molecules toxic activity MYC-overexpressing thymocytes used human
    T cell line screen small molecules synergize Notch inhibitors. identified antipsy-
    chotic drug perphenazine screens ability induce apoptosis fish, mouse, human
    T cells. Using ligand-affinity chromatography coupled mass spectrometry, identified protein
    phosphatase 2A (PP2A) perphenazine target. T cell lines treated perphenazine exhibited rapid
    dephosphorylation multiple PP2A substrates subsequent apoptosis.  shRNA knockdown
    specific PP2A subunits attenuated perphenazine activity, indicating PP2A mediates drugâ€™s anti-
    leukemic activity. Finally, human T-ALLs treated perphenazine exhibited suppressed cell growth     dephosphorylation PP2A targets vitro vivo. findings provide mechanistic explanation     recurring identification phenothiazines class drugs anticancer effects. Furthermore,     data suggest pharmacologic PP2A activation T cancers driven hyperphosphorylated
    PP2A substrates therapeutic potential.

Introduction                                                                            mutations NOTCH1 occur T variously stimulate
T cell acute lymphoblastic leukemia (T  aggressive                        NOTCH1 proteolysis generation ICN1 decrease ICN1
cer affecting mainly adolescents young adults. Intensified                          turnover, enhancing expression ICN1 target genes. treatment regimens improved outcomes, patients                             important direct targets ICN1 context fail conventional therapy dismal prognosis, T                            T cells MYC (6â€“8);  enforced expression MYC remains fatal 20  children 50  adults                            rescue human T cell lines NOTCH1 inhibition (6, 9)
(1â€“3). New therapies desperately needed patients                       MYC transgenes drive T development mouse (10)
poor-prognosis groups.                                                                  zebrafish (11, 12) models.  NOTCH1 activation   common genetic aberrations T acti-                          MYC overexpression sufficient T development, indi-
vating mutations NOTCH1 (4), transmembrane receptor                                cating establishment maintenance T depends converted transcriptional activator series                    additional cooperative genetic epigenetic events dysregulate
proteolytic cleavage events, carried                    signaling pathways.  activating NOTCH1 mutations
intramembranous protease Î³-secretase (5). Î³-Secretase cleavage                          diverse collection recurrent muta-
allows intracellular domain NOTCH1 (ICN1) translocate                         tions human T (13). frequent muta- nucleus form transcriptional activation complex.                       tions activate PI3K/AKT signaling pathway (14),                                                                                         complex interrelationship NOTCH signaling T cells
Authorship note: Alejandro Gutierrez, Li Pan, Richard W.J. Groen, Frederic Baleydier,   (15) promising therapeutic target disease (16). Alex Kentsis contributed equally work.                                        Repurposing FDA-approved drugs attractive approach
Conflict  authors declared conflict exists.    drug discovery, principle enable rapid translation Citation article: J Clin Invest. 2014;124(2):644â€“655. doi:10.1172/JCI65093.    clinic. Using 2 complementary screens, identified phenothi-

644	                                 Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014
                                                                                                                                     research article




Figure 1
Zebrafish screen small molecules toxic MYC-overexpressing thymocytes.   Primary screen design. (B) Hits primary
screen. Arrow denotes result obtained PPZ (C). Representative images DMSO (control) PPZ-treated zebrafish larvae. (D) Dose-
response curve secondary screen PPZ, 6 zebrafish larvae treated concentration. Drug doses higher 10 Î¼M induced general
toxicity  shown). Error bars = SD.


azines class drugs NOTCH-independent antiâ€“T                     logically gene expression (11, 12, 23), wanted activity. Phenothiazines used 50 years neu-                exploit model vivo drug discovery. developed
roleptic-type antipsychotic medications. antipsychotic effects               fluorescence-based screen designed identify small phenothiazines correlate ability block dopamine                 molecules selectively cytotoxic MYC-overexpressing
receptors, broad array activities described,            thymocytes. Heterozygous zebrafish carrying tandem rag2:MYC-
including antitumor effects. basis antiproliferative                 ER;mitfa transgene (created cointegration rag2:MYC-ER activities phenothiazines uncertain variously               wild-type mitfa transgenes genomic locus) mated
attributed number mechanisms, including inhibition                    rag2:dsRed2 homozygous animals, generating rag2:MYC-ERâ€“pos-
PKC (17), calmodulin (18), PI3K/AKT signaling (18â€“21),                   itive â€“negative embryos express rag2:dsRed2. crosses
cer stem cell activity (22).                                                     performed nacre pigmentâ€“mutant background   Using quantitative mass spectrometry analyze drug-protein                   melanophores absent homozygous mitfa-inactivating
binding proteome-wide, identified tumor suppressive ser-                  mutations (24). rescue pigmentation defect fish car-
ine/threonine phosphatase protein phosphatase 2A (PP2A)                     rying rag2:MYC-ER;mitfa transgene allowed distinguish
new phenothiazine target (Alex Kentsis James E. Bradner,                 MYC-ERâ€“positive â€“negative zebrafish 3 days post-fertiliza-
sonal correspondence). Phenothiazines stimulate rapid dephos-                    tion (dpf) (Figure 1A). 3 dpf, zebrafish larvae arrayed phorylation multiple PP2A targets implicated tumor cell                    96 plates (3 larvae  incubated 12.5 Î¼M drug growth survival cells, antitumor effects T                4-hydroxytamoxifen activate MYC-ER fusion protein. cells vitro vivo. findings provide likely explanation            days later, microscopy performed assay thymic fluorescence, recurrent discovery phenothiazines screens com-                scored 3 (normal), 2 (intermediate), 1 (weak), 0
pounds anticancer effects, point new rational drug combi-                 fluorescence) (Supplemental Figure 1; supplemental material
nations consideration treatment NOTCH-driven cancers                   available online article; doi:10.1172/JCI65093DS1). T  provide additional impetus development                    compound induced complete loss fluorescence 1 fish testing PP2A activators wide variety cancers.                     weak fluorescence 2 3 larvae  considered hit
                                                                                 primary screen. Compounds induced death Results                                                                          larvae generalized developmental abnormalities excluded
Zebrafish screen small molecules activity MYC-overexpress-      analysis. libraries bioactive small molecules
ing thymocytes. previously developed zebrafish model MYC-                comprising 4,880 FDA-approved drugs, drug-like small molecules,
induced T closely resembles human disease morpho-                   natural products screened fashion.

	                              Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014	                645
research article




Figure 2
Results screen small molecule inhibitors synergize Î³-secretase inhibitor compound E suppress growth human
T cell line KOPT-K1. KOPT-K1 cells incubated 384 format small molecules Broad Institute bioactives collection presence   absence (B) GSI (compound E, 0.1 Î¼M) duplicate. effects drugs cell growth assessed 2 days incubating CellTiter-Blue (Promega additional 4 hours, replicate compound measurement converted score
relative corresponding DMSO-control distribution, described ChemBank (70). (C) ChemBank composite scores computed combine replicates condition (+GSI â€“GSI), allowing assays considered single plot;  sought compounds synergistic GSI, e., score negative composite presence GSI effect absence GSI. express preferences quantitatively, devised 2-assay score (D) scales +GSI composite extent points negative direction extent exceeds â€“GSI composite  Methods); 330 compounds tested met initial criterion
(scale factor > 0.5), 43 compounds, including PPZ (inset), statistically distinguishable DMSO-control distribution. Methods Supplemental Figure 4 additional details; screen data available ChemBank  Methods).



  did identify compounds selectively                 tion) confirmed PPZ active MYC-overexpressing
toxic MYC-overexpressing thymocytes, multiple compounds                     thymocytes dose-dependent manner (Figure 1D). activity MYC-positive -negative thymocytes                 Human T screen small molecules synergize Î³-secretase identified. hits numerous glucocorti-                    inhibitors. parallel, conducted cell-based screen coids, known inducers thymocyte apoptosis,                Broad Institute bioactives chemical library collection (3,194 com- conventional chemotherapeutics induce DNA dam-                    pounds) identify drugs synergistically suppress growth
age (alkylating agents, topoisomerase inhibitors) (Figure 1B               T cells combination gamma-secretase inhibitors
Supplemental Table 1). compounds mainstays                   (GSI). Roughly thirds small molecules collection contemporary T therapy, validating utility              (n = 2108) overlap compounds screened zebrafish. approach. number novel compounds identified,                    screen conducted KOPT-K1 cells, NOTCH1-dependent
including perphenazine (PPZ), FDA-approved phenothiazine                    T cell line overexpresses transcription factor TAL1, antipsychotic (Figure 1, B C, Supplemental Table 1). Sec-              feature associated relatively poor prognosis disease.
ondary screening zebrafish larvae (n = 6 larvae concentra-              used combination GSI dexamethasone, known

646	                         Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014
                                                                                                                                    research article

                                                                                Figure 3
                                                                                PPZ subset related phenothiazines active estab-
                                                                                lished zebrafish T    Representative images zebrafish                                                                                 established MYC-induced T treated DMSO PPZ (1 Î¼M).
                                                                                (B) Rate T regression zebrafish established MYC-
                                                                                induced T  treated 1 Î¼M indicated compound. mini-
                                                                                mum 8 zebrafish analyzed condition.


                                                                                fore elected study effects T cells greater                                                                                  tested PPZ zebrafish established tumors                                                                                 PPZ active established MYC-induced T aris-
                                                                                ing nonconditional rag2:EGFP-MYC transgenic zebrafish line
                                                                                (Figure 3, B), indicating activity independent                                                                                 4-hydroxytamoxifen conditional MYC-ER fusion transgene
                                                                                used zebrafish-based screen. Activating Notch mutations
                                                                                absent tumors arising model (26);  drugs                                                                                 score model Notch-independent mecha-
                                                                                nisms. tested activity series structurally related
                                                                                phenothiazines 2 phenothiazines, prometha-
                                                                                zine chlorpromazine, antileukemic activity zebrafish
                                                                                1 Î¼M concentration, chlorprothixene pimethixene
                                                                                lacked activity established T model (Figure 3B).
                                                                                  extended studies PPZ phenothiazines                                                                                 mammalian T cell lines. PPZ single agent suppressed                                                                                 growth KOPT-K1 cells, cell line used human T                                                                                 screen (Figure 4A), combination PPZ GSI caused
                                                                                moderately synergistic growth suppression KOPT-K1 cells synergistic combination (25), positive control. initially               second human NOTCH1-dependent T cell line, DND41
performed isobologram analysis select concentrations GSI                  (Figure 4B), judged isobologram analysis (Supplemental
(compound E, 100 nM) dexamethasone (200 nM)                       Table 2). Similar synergistic interactions PPZ GSI synergistic growth inhibitory effect KOPT-K1 cells (Supple-                observed notch1-dependent murine T cell lines 142
mental Figure 2) used concentrations drugs                    (Figure 4C Supplemental Table 2) 144 (Supplemental Table screen optimization pilot studies. final conditions                2), harbor transgene driving expression constitu-
selected, GSI versus GSI plus dexamethasone produced score                  tively active kras acquired activating mutations notch1 0.74 (Supplemental Figure 3); point reference, screens                (27). PPZ suppressed growth SUPT13 (Figure 4D), scores greater 0.5 taken having high probabil-             GSI-insensitive human T cell line lacks NOTCH1
ity detecting true positives.                                                mutations, PF382, GSI-insensitive human T cell line
  screened Broad Institute bioactives library KOPT-K1            expresses constitutively active mutated form NOTCH1
cells according strategy shown Supplemental Figure 4.              (Supplemental Table 2). GSI-insensitive cell lines, little
brief, GSI/bioactive-compound interaction assessed inde-                 interaction PPZ GSI observed terms pendently scoring effects GSI plus bioactive compound               cell numbers (Figure 4D) isobologram analysis (Supplemental
(Figure 2A) effects bioactive compound                    Table 2), suggesting  zebrafish T  phenothiazines
(Figure 2B). identify compounds synergize GSI,                  antileukemic effects mammalian T cell lines looked data using 2 different approaches.  com-                 Notch-independent.
bined replicate data sets plotted composite scores                mechanism T growth suppression PPZ inves-
measure difference control state) presence               tigated human cell lines zebrafish (Figure 5). PPZ treat-
absence GSI (Figure 2C). scaled composite score                ment human murine T cell lines induced apoptosis, presence GSI fashion assessed screened mol-            assessed appearance sub-G1 DNA fraction (Figure 5,
ecule extent suppressed T cell growth              B), increased caspase activity (Figure 5, C D), presence GSI  +GSI composite score) extent              increased annexin V staining (Supplemental Figure 5A), effects suppression exceeded observed absence              enhanced cotreatment GSI (Figure 5,  B, D,
GSI  called 2-assay score; Figure 2D). Using metrics,          Supplemental Figure 5B). tested activity PPZ reproducible set synergistic â€œhitsâ€? totaled 43 3,194 compounds            established T tumors induced rag2:EGFP-MYC;rag2:EGFP-
screened, 1.3  compounds  structure identity             BCL2 double-transgenic zebrafish (Figure 5E), compounds, ChemBank [http://chembank.broadinstitute.org/                    BCL2 overexpression completely blocked activity PPZ chemistry/search/execute.htm?id=5685551]). Notably, PPZ                    zebrafish tested (n = 9), confirming PPZ acts induction scored hits KOPT-K1 cell line screen.                  mitochondrial apoptosis.
  Verification antileukemic activity PPZ. Taken  2         PPZ binds activates PP2A tumor suppressor. Phenothiazines screens suggested PPZ targets conserved regulator benign              best known inhibitors dopaminergic signaling. Multiple dopa- malignant T cell progenitor growth viability,               receptors expressed T lineage cells proposed

	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014	                  647
research article




Figure 4
Activity PPZ related phenothiazines mammalian T cell lines.   Growth suppression KOPT-K1 cells indicated phe-
nothiazines, expressed IC50. (Bâ€“D) Effects compound E (GSI) PPZ growth Notch1-dependent human KOPT-K1 DND41
T cells (B), Notch1-dependent murine 142 T cells (C), NOTCH1-independent human SUP-T13 T cells (D). experiment, condition assayed triplicate, experiments repeated twice. Bâ€“D, PPZ compound E used 10 Î¼M 0.1 Î¼M, respectively, (C) PPZ compound E used 3 Î¼M 6 nM, respectively.


 regulate immune function (28).  structurally unre-             protein targets KOPT-K1 T cell lysates labeled
lated dopamine inhibitors haloperidol, domperidone, clozapine             stable isotopes (SILAC) (31). protein pull-downs were toxic Myc-overexpressing thymocytes, effect             presence absence competitor phenothiazines
T progression zebrafish, did affect human KOPT-K1              varying IC50 KOPT-K1 cell growth inhibition, dis-
T cell growth (data shown). Conversely, promethazine,               placement individual binding proteins fluorous PPZ
phenothiazine does inhibit dopaminergic signaling (29),              matrix assessed quantitative mass spectrometry. decreased growth zebrafish T-ALLs human KOPT-K1                    rank ordered binding proteins based correlation T cells (Figure 3B Figure 4A). Taken  data             displacement drug drugâ€™s IC50 KOPT-K1 cells. strongly suggest inhibition dopaminergic signaling unre-           approach identified PPP2R1A protein binding
lated antileukemic activity compounds.                        affinity correlated closely biologic activities   reported activity phenothiazines abrogate             phenothiazines tested (Figure 6, B). PPP2R1A AÎ±
mitogenic signaling inhibition calmodulin (30),               scaffolding subunit protein phosphatase PP2A, sub-
broad roles calcium-dependent intracellular signaling.             sequent work confirmed PPZ directly binds purified PP2A noted W13, relatively selective calmodulin inhibitor,            low micromolar concentrations (Alex Kentsis James E. Brad-
highly toxic zebrafish larvae low nanomolar concentrations              ner, personal communication).
(data shown), presumably calmodulin inhibition                   PP2A conserved heterotrimeric phosphatase compatible survival.  difficult exclude          different isoforms, comprising scaffolding subunit, vari- contribution calmodulin inhibition observed                    able regulatory B subunit, catalytic C subunit (32, 33). Best
effects phenothiazines, calmodulin inhibition explain               known tumor suppressor targeted SV40 small t anti- activity phenothiazines zebrafish screen.                       gen, PP2A target oncogenic microRNA miR-19 (34),
  left challenge identifying                collaborates activated Notch1 promote T devel-
molecular target responsible activity phenothi-           opment. tumor-suppressive activity PP2A believed azines screens. address issue, devised quantita-          mediated ability dephosphorylate diverse substrates
tive mass spectrometry approach, termed activity correlation pro-             implicated oncogenic signaling, including AKT (35), p70S6K
teomics, offers improve identification biologically            (36), MYC (37â€“39), ERK (40, 41), BAD (42, 43).  relevant targets pleiotropic drugs. Briefly, used fluorous-             antileukemic effects PPZ phenothiazines T tagged PPZ fluorous ligand-affinity chromatography pull-               mediated PP2A, drugs stimulate

648	                        Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014
                                                                                                                                    research article

                                                                                                                         Figure 5
                                                                                                                         PPZ induces T cell apoptosis.
                                                                                                                          B) DNA histograms human
                                                                                                                         KOPT-K1 mouse 142 T                                                                                                                          cells, respectively, treated                                                                                                                          compound E (GSI) PPZ                                                                                                                          combination 96 hours.
                                                                                                                         (C D) PPZ increases caspase
                                                                                                                         3/7 activity KOPT-K1 cells                                                                                                                          combination GSI (com-
                                                                                                                         pound E), used indicated
                                                                                                                         concentrations 48 hours. (E)                                                                                                                          representative rag2:EGFP-MYC;
                                                                                                                         rag2:EGFP-BCL2 double-trans-
                                                                                                                         genic zebrafish treated 1 Î¼M
                                                                                                                         PPZ shown. PPZ activity
                                                                                                                         bcl2-transgenic zebraf-
                                                                                                                         ish tested (n = 8).




PP2A activity. predicted, incubation KOPT-K1 cells PPZ               expanded passage NSG mice sensitivity PPZ led rapid dephosphorylation PP2A substrates AKT, ERK,                 newly described serum-free culture T cells p70S6K, MYC, BAD (Figure 6, Câ€“E), effects abrogated               relies completely defined medium feeder cells expressing addition phosphatase inhibitor okadaic acid (Figure 6D),              Notch ligand DLL-1 (46). noted low micromolar levels inhibitor PP2A. Total AKT, ERK, p70S6K, BAD protein                   PPZ resulted dephosphorylation multiple PP2A targets
levels unaffected PPZ, levels MYC protein fell               (AKT, p70S6K, BAD) impaired growth 4 T-ALLs test-
(Figure 6E), line prior reports showing PP2A-mediated              ed conditions (Figure 8). Variable sensitivity GSI dephosphorylation MYC residue S62 enhances MYC degrada-                      variable interaction GSI PPZ noted (Figure 8).
tion (37). addition, noted effects PPZ PP2A                tested independent series primary T-ALLs sec-
substrates growth T cell lines KOPT-K1                  ond culture relies high levels human serum phenocopied FTY720 (Fingolimod) (Supplemental Figure 6,                    observed similar results, lines growth inhibited low B), FDA-approved immunomodulatory drug previously                        micromolar concentrations PPZ (Supplemental Figure 7).
shown activate PP2A low micromolar concentrations (44, 45).                 primary human T lines, hTALL2, grew suffi- contrast, calmodulin inhibitor W13 effect PP2A                 ciently serum-free culture permit luciferiza-
targets p70S6K (Supplemental Figure 6C).                                tion retrovirus, facilitated drug testing vivo.   determine PP2A required activity PPZ,             carried mice bearing calcium phosphate scaffolds used shRNA knock PP2A AÎ± scaffolding subunit.                 seeded human marrowâ€“derived mesenchymal stem cells,
PP2A AÎ± knockdown impaired PPZ-induced dephosphoryla-                       approach allows drug testing â€œhumanizedâ€?
tion PP2A targets (Figure 7A) desensitized KOPT-K1                  microenvironment. Treatment mice PPZ (10 mg/kg
cells growth-suppressive effects PPZ (Figure 8B).                     intraperitoneally daily) caused significant decrease growth shRNA knock catalytic PP2A CÎ± subunit similar                     hTALL2 cells scaffolds (Figure 9A) murine spleen
effects (Figure 7, C D). Taken  data strongly                (Figure 9B). Importantly, single dose PPZ (10 mg/kg) led
suggest growth-suppressive effects PPZ T cells               dephosphorylation PP2A targets AKT, p70S6K, mediated stimulation PP2A activity.                                  BAD hTALL2 blasts vivo (Figure 9C). results   PPZ activates PP2A antileukemic effects primary human              PPZ produce antileukemic effects stimulate PP2A activity
T cells vitro vivo. results hand, remained       primary T lymphoblasts doses tolerated mice. determined PPZ inhibit growth primary
T cells vitro vivo,  antileukemic               Discussion
effects associated dephosphorylation PP2A targets.                 NOTCH1 compelling therapeutic target T  address issue vitro, tested series primary human             activity GSIs single agents T preclinical models (47)
T-ALLs (summarized Supplemental Table 3)                       clinical trials (48) modest, suggesting need 
	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014	                         649
research article




Figure 6
PPZ binds PP2A leads rapid dephosphorylation PP2A targets KOPT-K1 T cells.   Activity correlation proteomics revealed biologic activity phenothiazines correlates closely binding affinity PPP2R1A, scaffolding AÎ± subunit PP2A
phosphatase, described (Alex Kentsis James E. Bradner, personal correspondence). (B) Structures phenothiazines tested. (C)
Effects PPZ phosphorylation AKT, ERK, p70S6K, BAD. Lysates prepared 15 minutes treatment. (D) PP2A inhibitor
okadaic acid (OA) antagonizes PPZ-mediated dephosphorylation PP2A substrates. Lysates prepared 15 minutes PPZ treatment.
(E) Effects PPZ MYC phosphorylation protein levels. Lysates prepared 30 minutes 6 hours PPZ treatment. D, cells pretreated okadaic acid 30 minutes prior addition PPZ.



combine Notch pathway inhibitors compounds                     GSI combination TOR inhibitors (9, 47), PI3K inhibi-
activity disease. used complementary screens discov-             tors (58), MAPK inhibitors (58) increased activity er small molecules Notch-independent antiâ€“T activity.                 GSI T  PP2A blunts signaling multiple small molecules scoring screens glucocorti-                  â€œnodesâ€? downstream surface receptors RAS dephos-
coids, providing support use GSIs glucocorti-               phorylation signaling intermediates ERK (40, 41),
coids combination relapsed/refractory T (25). previ-               AKT (35), p70S6K (36) inhibit growth 
ously unidentified hit emerging screens PPZ,                 regulating MYC (37â€“39) promote apoptosis dephosphory- shown suppress growth piscine, murine,                 lating BAD (42, 43). support PPZ acting PP2A activa-
human T-ALLs induction apoptosis. effects                  tor, data PPZ treatment affects phosphorylation
PPZ linked biochemical, cell biological, genetic studies           PP2A substrates, shRNA knockdown activation PP2A, tumor-suppressive protein phosphatase.                PP2A catalytic scaffolding subunits impaired antileukemic ability PPZ activate PP2A represents likely                 activity PPZ. Withdrawal Notch signaling treatment mechanism previously unexplained ability phenothi-                  GSI inhibitors interferes growth T cells
azines downregulate PI3K/AKT signaling explain                  number mechanisms, including downregulation recurrent identification compounds unbiased screens                MYC (6, 8, 59), 7R (55, 60), IGF-R1 (57), suppression agents antineoplastic activity (18â€“21, 49â€“53).                        PI3K/AKT signaling (61). partially overlapping effects   Given signaling mutated KRAS (54) receptors                PP2A stimulation Notch withdrawal key mitogenic signal- 7R (55, 56) IGF-R1 (57) synergize Notch signaling            ing pathways predict drug combinations hit induce maintain T growth, combinations agents                  targets additive growth-suppressive effects antagonize downstream effectors pathways attractive               Notch-dependent T cells, consistent findings therapeutic options disease.  prior work shown              GSI phenothiazines.

650	                         Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014
                                                                                                                                    research article

                                                                                                                       Figure 7
                                                                                                                       PP2A AÎ± (structural) CÎ± (cata-
                                                                                                                       lytic) subunits required                                                                                                                        growth-suppressive activity PPZ                                                                                                                        T cells.   Western blot analysis
                                                                                                                       KOPT-K1 T cells infected                                                                                                                        shRNA specific GFP (control)                                                                                                                        PP2A AÎ± treated doses
                                                                                                                       PPZ shown. (B) Effect                                                                                                                        shRNAs KOPT-K1 T cell
                                                                                                                       viability day 5 treatment                                                                                                                        control 5 Î¼M PPZ. (C) Western
                                                                                                                       blot analysis KOPT-K1 T cells
                                                                                                                       infected shRNA specific GFP
                                                                                                                       (control) PP2A CÎ± treated
                                                                                                                       doses PPZ shown. (D)
                                                                                                                       Effect shRNAs KOPT-
                                                                                                                       K1 cell viability treatment                                                                                                                        control (DMSO) 7.5 Î¼M PPZ.                                                                                                                        C, cells treated PPZ
                                                                                                                       30 minutes.




   data suggest combination GSI PP2A activator               Zebrafish small molecule screen. 3 dpf, transgenic zebrafish larvae attractive strategy relapsed/refractory T           expressing rag2:Myc-ER rag2:dsRed2 transgenes (12) arrayed merit consideration Notch-associated tumors,              96 plates (3 larvae  exposed individual small molecules
mantle cell lymphoma (62), chronic lymphocytic leukemia (63â€“65),                doses 12.5 Î¼M small molecules 1.25 Î¼M bioactive lipids, breast cancer (66), failed conventional therapies. limi-        50 Î¼g/l (129 nM) 4-hydroxytamoxifen activate Myc-ER
tation PPZ phenothiazines marked extra-             transgene, antibiotics reduce bacterial overgrowth (25 units/ml
pyramidal effects, limitation considering            penicillin, 25 mg/ml streptomycin, 5 mg/ml meropenem). Small
drugs therapeutic agents cancer, activities antipsy-          molecules following small molecule libraries: Lopac 1280
chotic drugs low nanomolar concentrations, substantially               (n = 1280 compounds; Sigma-Aldrich); ICCB known bioactives (n = 480 levels needed activate PP2A. possible allevi-      compounds; Enzo Life Sciences); Prestwick Chemical Library (n = 1200
ate drawbacks engineering phenothiazine derivatives           compounds; Prestwick Chemical); Spectrum Collection (n = 2000 potent PP2A activators lack activity dopamine recep-            compounds; MicroSource Discovery Systems). 4 days treatment,
tors; promethazine example phenothiazine antileuke-             thymic fluorescence individual larvae assessed fluorescence
mia activity does avidly bind dopamine receptors, suggesting           microscopy. Small molecules induced general toxicity zebrafish 2 activities separated. alternative approach         larvae discarded. wells 96 plate dedicated use PP2A activators favorable toxicity profiles            positive (dexamethasone 12.5 Î¼M) negative (DMSO) controls. FDA approved, FTY720 (44). FTY720 potent                  KOPT-K1 cell line screen. screening method used human T inhibitor sphingosine-1-phosphate receptor activity          cells shown schematically Supplemental Figure 4. Briefly, KOPT-K1
preclinical models variety cancers, including chronic lympho-           cells (10,000  seeded using MATRIX WellMate 384 cytic leukemia (67), chronic myelogenous leukemia blast crisis (45),            plates RPMI supplemented 10  fetal calf serum, glutamine, pen-
B cell acute lymphoblastic leukemia (45), mantle cell lymphoma              icillin/streptomycin 37Â°C 5  CO2. assess interactions (68).  phenothiazines, levels FTY-720           GSI (compound E) bioactive compounds, wells sequen-
required PP2A stimulation low micromolar range, mak-             tially â€œpinnedâ€? CyBi duplicate compound E (100 nM;
ing ideal clinical lead. likely active       +GSI) DMSO (â€“GSI) followed small molecule Broad Insti-
selective PP2A-stimulating compounds need developed               tute bioactives collection. Bioactive library compounds delivered robust clinical impact anticancer drugs. Iden-            volume 25 nl produce final concentration ranged 5 Î¼M
tification PP2A-stimulating effect phenothiazines provides            10 Î¼M. Positive controls consisted dexamethasone (200 nM) new path forward development small molecules                  dexamethasone (200 nM) plus GSI (100 nM compound E), negative
improved PP2A diminished target activities.                          controls consisted vehicle (DMSO) GSI (100 nM compound E)
                                                                                 48 hours treatment, CellTiter-Blue added 4 hours
Methods                                                                         viable cell numbers determined measuring fluorescence 595 nm
Transgenic zebrafish lines. rag2:MYC-ER;mitf, rag2:dsRed2, rag2:EGFP-       plate reader. High-throughput screening data processed sepa-
MYC, rag2:EGFP-BCL2 transgenic lines previously                   rately 2 assays (Figure 2A: +GSI; Figure 2B: â€“GSI) deposition described (12, 23, 69).                                                         ChemBank described (70). Complete raw processed data 
	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014	                        651
research article

                                                                                                           â€“ GSI) Ã— F, clearly discriminates com-
                                                                                                           pounds plotted GSI
                                                                                                           (Figure 2D). Using initial cutoff F > 0.5,
                                                                                                           identified 330 compounds, 43
                                                                                                           compounds statistically distinct                                                                                                            2-assay DMSO distribution, modeled                                                                                                            multivariate normal distribution, sub-
                                                                                                           jected Holm-Bonferroni multiple hypothesis
                                                                                                           test correction.
                                                                                                              Cell culture. cells cultured 37Â°C
                                                                                                           5  CO2. Established cell lines grown
                                                                                                           RPMI supplemented 10  fetal calf
                                                                                                           serum, glutamine, penicillin/streptomycin.
                                                                                                           Primary human T-ALLs grown short-
                                                                                                           term cultures MS5-DLL1 stromal cells                                                                                                            high-serum (71) serum-free defined
                                                                                                           conditions (46) described.
                                                                                                              Cell viability assays. Cell viability measured
                                                                                                           using CellTiter-Blue cell viability assay kit
                                                                                                           (Promega). Cells plated black-walled
                                                                                                           96 plates treated chemical com-
                                                                                                           pounds. 20 Î¼l CellTiter-Blue reagent
                                                                                                           added wells, contained
                                                                                                           100 Î¼l cells. 4 hours 37Â°C, fluores-
                                                                                                           cence recorded SpectraMax M3 micro-
                                                                                                           plate reader (Molecular Devices) measure
                                                                                                           resazurin reduction.
                                                                                                              Isobologram analysis. determine                                                                                                            drugs synergistic antileukemia cell growth
                                                                                                           effects, cells incubated various concen-
                                                                                                           trations drugs 48 hours incubat-
                                                                                                           ed CellTiter-Blue addition 4 hours.
                                                                                                           Cell numbers determined measuring
                                                                                                           fluorescence 595 nm plate reader. Data
                                                                                                           processed subjected isobologram
                                                                                                           analysis (72) using CalcuSyn determine                                                                                                            combination index (CI) ED50. CI                                                                                                            0.7 ED50 taken indicative                                                                                                            synergistic interaction.
                                                                                                              Cell-cycle analysis. Cells washed                                                                                                            cold PBS fixed 90  ethanol overnight
                                                                                                           â€“20Â°C. Cells washed Figure 8                                                                                                   cold PBS resuspended propidium iodide
PPZ induces rapid dephosphorylation PP2A targets inhibits growth cultured primary (PI) staining solution (20 Î¼g/ml PI, 200 Î¼g/ml
human T cells.  D) Western blots showing effects incubation 15 minutes                                                                                                            DNAse-free RNAse  0.1  [v/v] Triton
indicated doses PPZ. (Eâ€“H) Effects GSI (compound E, 1 Î¼M) PPZ (5 Î¼M) combination cell growth relative vehicle-treated control cells. Cells grown defined X-100 PBS). Following incubation 37Â°C
medium MS5-DLL-1 feeder cells. Cell counts determined 3 days treatment.                   15 minutes, samples analyzed                                                                                                            FACSCalibur flow cytometer (BD Biosciences)
                                                                                                           using Cell Quest software.
screening experiments available ChemBank (http://chembank.             Apoptosis assays. Caspase 3 7 activities measured using Caspase-
broadinstitute.org/assays/view-project.htm?id=1000654). combine Glo 3/7 assay (Promega). Following treatment KOPT-K1
results 2 assays quantitatively, defined trigonometric scaling cells DMSO, GSI, PPZ, GSI plus PPZ, 5,000 cells sam-
function express preferences   +GSI composite scores ple plated white-walled 96 plates final volume negative, (b) +GSI composite score amplitudes exceed â€“GSI compos- 100 Î¼l. equal volume Caspase-Glo 3/7 reagent added ite score amplitudes; compounds fall left DMSO   1 hour room temperature, luminescence mea-
trol distribution, main diagonal plot â€“GSI compos- sured SpectraMax M3 microplate reader (Molecular Devices). ite versus +GSI composite (Figure 2C). Using ratio ChemBank second measure apoptosis, cells stained annexin V PI
composite scores (â€“GSI/+GSI), defined Î¸ = arctan GSI GSI) using Apoptosis Detection Kit (BD Biosciences) manufacturerâ€™s
expressed scale factor F = cos(â€“Î¸)cos(2Î¸), 2 factors respec- instructions, analyzed FACSalibur flow cytometer (BD Bio-
tively expressing 2 preferences. 2-assay composite score, sciences) using Cell Quest software.

652	                            Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014
                                                                                                                                      research article




Figure 9
PPZ inhibits growth dephosphorylates PP2A targets primary human T cells vivo.  B) Effects treatment PPZ
(10 mg/kg/d) growth human hTALL2 cells NSG mice.   Effects tumor cell growth assessed measuring biolumines-
cence luciferized hTALL2 cells subcutaneous calcium phosphate scaffolds seeded human mesenchymal stem cells. Arrow indi-
cates time initiation PPZ treatment. *P < 0.0182. (B) Spleen weights treatment control mice times necropsy. *P < 0.05.
(C) Western blots prepared hTALL2 cells harvested engrafted mice 3 hours single dose PPZ (10 mg/kg). lane
corresponds different animal. blot stained phospho-p70S6K total p70S6K prepared second gel loaded samples run parallel.



   Murine xenograft assays. Retrovirus transfecting MLCP,          pLKO.1-puro shPP2A CÎ± obtained Dana Farber Cancer Institute
MSCV-based retrovector encoding firefly luciferase, mCherry, puro-            RNAi core facility. targeting sequence inserted pLKO.1-puro
mycin phosphotransferase, Phoenix GP/293T cells (provided                 shPP2A 5â€²-CCGGCCCATGTTGTTCTTTGTTATTCTCGAGAATAA-
David Williams, Boston Childrenâ€™s Hospital). Transduced human hTALL2              CAAAGAACAACATGGGTTTTT-3â€². pLKO.1-puro-GFP used T cells isolated based mCherry expression using FACSAria            shRNA control vector.
II SORP UV cell sorter (BD Biosciences). Luciferized hTALL2 cells               Chemicals. PPZ, chlorpromazine, chlorprothixene, pimethixene, pro-
injected intrascaffold NOD/SCID Î³-chain knockout (NSG) mice                  methazine, domeridone purchased Sigma-Aldrich. Com-
bearing subcutaneous biphasic calcium phosphate scaffolds seeded             pound E FTY720 purchased Enzo Life Sciences. Okadaic
mesenchymal stem cells followed tumor development using bio-              acid purchased LC Laboratories.
luminescence imaging described (73). assess antileukemic effects           Statistics. Statistical significance isobologram analyses determined PPZ, mice treated daily 10 mg/kg PPZ intraperitoneal           using Calcusyn, differences spleen weights determined injection T growth monitored bioluminescence. assess            t test, performed Prism software. Statistical analyses KOPT-K1 cell effect PPZ phosphorylation PP2A substrates T cells         lineâ€“screening data performed described Figure 2 legend vivo, mice bearing bone scaffolds loaded hTALL2 cells treated           Methods. vehicle single dose PPZ (10 mg/kg) intraperitoneally.             Study approval. animal studies approved Dana Farber 
hours later, cells harvested scaffold 2 Ã— 107 cells       cer Institute Animal Care Use Committee.
incubated human CD45 MicroBeads (Miltenyi Biotec). Beads subsequently washed cold PBS, pH 7.4, containing 0.5  BSA               Acknowledgments 2 mM EDTA, resuspended 500 Î¼l PBS. Bound cells                 PP2A AÎ± shRNA gift W.C. Hahn. wish thank
separated beads MS column using MACS Separator                   P. Ballerini, J. Landman-Parker, T. Leblanc,  Baruchel immediately lysed Western blot analyses.                                      HÃ´pital Trousseau HÃ´pital R DebrÃ© help collection    Western blotting antibodies. Cells washed cold PBS resus-    patient samples S. Blacklow advice technical 
pended lysis buffer (50 mM Tris, pH 8.0, 5 mM EDTA, 100 mM NaF,              ceptual aspects studies. work supported NIH
30 mM pyrophosphate, 2 mM molybdate, 2 mM vanadate, 1  NP-40) sup-                grants 1K08CA133103   Gutierrez) 5P01CA109901  T.
plemented protease inhibitors (Sigma-Aldrich). Cell lysates incu-       Look); Specialized Center Research grant Leukemia
bated ice 15 minutes centrifuged 15 minutes 12,000 g       Lymphoma Society  J.C. Aster J.E. Bradner); grants 4Â°C. Protein concentration measured Bradford assay (Bio-Rad),           William Lawrence Blanche Hughes Foundation   Gutierrez, equal amounts protein loaded SDS-polyacrylamide gels               J.C. Aster, T. Look, J.E. Bradner); grant Bear Neces- resolved electrophoresis. Proteins stained following transfer      sities Pediatric Cancer Foundation   Gutierrez); grants
PVDF membranes following specific antibodies: anti-pAKT(S473),           Ligue Nationale contre le Cancer, Association Laurette Fugain,
anti-AKT, anti-pERK(T202/Y204), anti-ERK, anti-pP70S6K(S389), anti-               Institut National du Cancer (INCA), UniversitÃ©s Paris Diderot P70S6K, anti-pBAD(S112), anti-BAD, anti-MYC, anti-PP2A subunit C              Paris Sud, INSERM, CEA Canceropole Ile France (StemPole)
 Cell Signaling Technology); pMYC(S62) (Abcam); antiâ€“                 F. Pflumio, S. Poglio, B. Uzan). R. Groen received fund-
Î²-actin (Sigma-Aldrich). Staining developed Super Signal West            ing People Programme (Marie Curie Actions) Euro-
Pico Chemiluminescent Substrate Super Signal West Dura Extended                pean Unionâ€™s Seventh Framework Programme FP7/2007-2013/
Duration Substrate (Thermo Scientific) 2 minutes room tempera-             REA grant agreement  302428.  Gutierrez research
ture documented exposure x-ray film (Kodak).                            fellow Gabrielleâ€™s Angel Foundation Cancer Research    PP2A shRNA knockdown. Knockdown PP2A AÎ± (encoded                         previous scholar American Society Hematology Harold
PPP2R1A) performed using pMKO.1-shAa vector described                  Amos Medical Faculty Development Program. T cell line
(74). Knockdown PP2A CÎ± (encoded PPP2CA) performed                 screen funded federal funds NCI Initia-

	                               Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014	                         653
research article

tive Chemical Genetics contract  N01 12400.                               Address correspondence   Thomas Look, Department Pedi-
content publication does necessarily reflect views                         atric Oncology, Dana-Farber Cancer Institute, 44 Binney St., Mayer
policies Department Health Human Services, does                             630, Boston, Massachusetts 02115, USA. Phone: 617.632.5826;
mention trade names, commercial products, organizations                                 Fax: 617.632.6989; E-mail: thomas_look@dfci.harvard.edu. imply endorsement Government.                                                        Jon C. Aster, Department Pathology, Brigham Wom-
                                                                                              s Hospital, 75 Francis St., Boston, Massachusetts 02115, USA.
Received publication October 1, 2013, accepted October                                Phone: 617.525.4370; Fax: 617.525.4422; E-mail: jaster@rics.bwh.
30, 2013.                                                                                     harvard.edu.
	 1.	Marks DI, et al. T-cell acute lymphoblastic leuke-             proliferation survival. Ann N Y Acad Sci. 2008;             regulatory subunit B56alpha associates c-myc
      mia adults: clinical features, immunopheno-                1138:393â€“403.                                                   negatively regulates c-myc accumulation. Mol
      type, cytogenetics outcome large           	 20.	Koren J, et al. Facilitating Akt clearance manipu-          Cell Biol. 2006;26(7):2832â€“2844.
      randomised prospective trial (UKALL XII/ECOG                  lation Hsp70 activity levels. J Biol Chem. 2010;   	 39.	Junttila MR, et al. CIP2A inhibits PP2A human
      2993). Blood. 2009;114(25):5136â€“5145.                         285(4):2498â€“2505.                                               malignancies. Cell. 2007;130(1):51â€“62.
	 2.	Goldberg JM, et al. Childhood T-cell acute lympho-       	 21.	Rho SB, Kim BR, Kang S. gene signature-based            	40.	Chen  et al. MAP kinases. Chem Rev. 2001;
      blastic leukemia: Dana-Farber Cancer Institute            approach identifies thioridazine inhibitor             101(8):2449â€“2476.
      acute lymphoblastic leukemia consortium experi-               phosphatidylinositol-3â€²-kinase (PI3K)/AKT path-           	 41.	Ugi S, Imamura T, Ricketts W, Olefsky JM. Protein
      ence. J Clin Oncol. 2003;21(19):3616â€“3622.                    way ovarian cancer cells. Gynecol Oncol. 2011;               phosphatase 2A forms molecular complex 	 3.	Ko RH, et al. Outcome patients treated                  120(1):121â€“127.                                                 Shc regulates Shc tyrosine phosphorylation
      relapsed refractory acute lymphoblastic leu-         	 22.	Sachlos E, et al. Identification drugs including           downstream mitogenic signaling. Mol Cell Biol.
      kemia: Therapeutic Advances Childhood                    dopamine receptor antagonist selectively tar-              2002;22(7):2375â€“2387.
      Leukemia Consortium study. J Clin Oncol. 2010;                cancer stem cells. Cell. 2012;149(6):1284â€“1297.       	42.	Chiang CW, et al. Protein phosphatase 2A acti-
      28(4):648â€“654.                                          	23.	Langenau DM, Feng H, Berghmans S, Kanki JP,                      vates proapoptotic function BAD inter-
	 4.	Koch U, Radtke F. Notch T  new players             Kutok JL, Look  Cre/lox-regulated transgenic                 leukin- 3-dependent lymphoid cells mecha-
      complex disease. Trends Immunol. 2011;32(9):434â€“442.          zebrafish model conditional myc-induced T                  nism requiring 14-3-3 dissociation. Blood. 2001;
	 5.	Kopan R, Ilagan MX. canonical Notch signal-                cell acute lymphoblastic leukemia. Proc Natl Acad               97(5):1289â€“1297.
      ing pathway: unfolding activation mechanism.              Sci U S  2005;102(17):6068â€“6073.                        	 43.	Chiang CW, et al. Protein phosphatase 2A dephos-
      Cell. 2009;137(2):216â€“233.                              	24.	Lister JA, Robertson CP, Lepage T, Johnson SL,                   phorylation phosphoserine 112 plays gate-
	 6.	Weng AP, et al. c-Myc important direct target            Raible DW. nacre encodes zebrafish microph-                   keeper role BAD-mediated apoptosis. Mol Cell
      Notch1 T-cell acute lymphoblastic leukemia/             thalmia-related protein regulates neural-                  Biol. 2003;23(18):6350â€“6362.	
      lymphoma. Genes Dev. 2006;20(15):2096â€“2109.                   crest-derived pigment cell fate. Development. 1999;       	44.	Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya
	 7.	Sharma VM, et al. Notch1 contributes mouse                  126(17):3757â€“3767.                                              T. novel immunosuppressive agent FTY720
      T-cell leukemia directly inducing expression     	 25.	Real PJ, et al. Gamma-secretase inhibitors reverse              induced Akt dephosphorylation leukemia cells.
      c-myc. Mol Cell Biol. 2006;26(21):8022â€“8031.               glucocorticoid resistance T cell acute lympho-               Br J Pharmacol. 2003;138(7):1303â€“1312.
	 8.	Palomero T, et al. NOTCH1 directly regulates                   blastic leukemia. Nat Med. 2009;15(1):50â€“58.              	 45.	Neviani P, et al. FTY720, new alternative treat-
      c-MYC activates feed-forward-loop transcrip-      	 26.	Blackburn JS, et al. Notch signaling expands pre-             ing blast crisis chronic myelogenous leukemia       tional network promoting leukemic cell growth.                malignant pool T-cell acute lymphoblastic leuke-             Philadelphia chromosome-positive acute lympho-
      Proc Natl Acad Sci U S  2006;103(48):18261â€“18266.           mia clones affecting leukemia-propagating               cytic leukemia. J Clin Invest. 2007;117(9):2408â€“2421.
	 9.	Chan SM, Weng AP, Tibshirani R, Aster JC, Utz                  cell frequency. Leukemia. 2012;26(9):2069â€“2078.           	46.	Yost AJ, et al. Defined, serum-free conditions       PJ. Notch signals positively regulate activity   	 27.	Ashworth TD, et al. Deletion-based mechanisms                   vitro culture primary human T blasts.
      mTOR pathway T-cell acute lymphoblastic leu-               Notch1 activation T  key roles RAG                Leukemia. 2013;27(6):1437â€“1440.
      kemia. Blood. 2007;110(1):278â€“286.                            recombinase conserved internal translational        	 47.	Cullion K, et al. Targeting Notch1 mTOR
	 10.	Felsher DW, Bishop JM. Reversible tumorigenesis               start site Notch1. Blood. 2010;116(25):5455â€“5464.            pathways mouse T model. Blood. 2009;
      MYC hematopoietic lineages. Mol Cell. 1999;       	28.	Pacheco R, Prado CE, Barrientos MJ, Bernales S.                  113(24):6172â€“6181.
      4(2):199â€“207.                                                 Role dopamine physiology T-cells         	48.	DeAngelo DJ, Stone RM, Silverman LB, Aster
	11.	Langenau DM, et al. Myc-induced T cell leu-                    dendritic cells. J Neuroimmunol. 2009;216(1â€“2):8â€“19.            JC. phase clinical trial Notch inhibitor
      kemia transgenic zebrafish. Science. 2003;           	 29.	Horn  Post ML, Kennard O. Dopamine receptor                  MK-0752 patients T-cell acute lympho-
      299(5608):887â€“890.                                            blockade neuroleptics, crystallographic               blastic leukemia/lymphoma (T  	12.	Gutierrez  et al. Pten mediates Myc oncogene                 study. J Pharm Pharmacol. 1975;27(8):553â€“563.                   leukemias. J Clin Oncol. 2006;24:6585.
      dependence conditional zebrafish model T        	 30.	Jaszczyszyn  et al. Chemical structure pheno-        	 49.	Sachlos E, et al. Identification drugs including       cell acute lymphoblastic leukemia. J Exp Med. 2011;           thiazines biological activity. Pharmacol              dopamine receptor antagonist selectively tar-
      208(8):1595â€“1603.                                             Rep. 2012;64(1):16â€“23.                                          cancer stem cells. Cell. 2012;149(6):1284â€“1297.
	 13.	Weng AP, et al. Activating mutations NOTCH1          	31.	Ong SE, et al. Identifying proteins           	50.	Zhelev  et al. Phenothiazines suppress prolif-
      human T cell acute lymphoblastic leukemia.                 small-molecule probes drugs bind cells. Proc             eration induce apoptosis cultured leukemic
      Science. 2004;306(5694):269â€“271.                              Natl Acad Sci U S  2009;106(12):4617â€“4622.                    cells influence viability 
	 14.	Gutierrez  et al. High frequency PTEN, PI3K,       	 32.	Shi Y. Serine/threonine phosphatases: mechanism                 mal lymphocytes. Phenothiazines leukemia.
      AKT abnormalities T-cell acute lymphoblas-             structure. Cell. 2009;139(3):468â€“484.                   Cancer Chemother Pharmacol. 2004;53(3):267â€“275.
      tic leukemia. Blood. 2009;114(3):647â€“650.               	 33.	Virshup DM, Shenolikar S. promiscuity             	 51.	Gil-Ad  Shtaif B, Levkovitz Y, Dayag M, Zeldich
	 15.	Palomero T, Ferrando  Oncogenic NOTCH1                  precision: protein phosphatases makeover.                 E, Weizman  Characterization phenothiazine-
      trol MYC PI3K: challenges opportuni-               Mol Cell. 2009;33(5):537â€“545.                                   induced apoptosis neuroblastoma glioma
      ties anti-NOTCH1 therapy T-cell acute lym-       	34.	Mavrakis KJ, et al. Genome-wide RNA-mediated                     cell lines: clinical relevance possible applica-
      phoblastic leukemias lymphomas. Clin Cancer               interference screen identifies miR-19 targets                tion brain-derived tumors. J Mol Neurosci. 2004;
      Res. 2008;14(17):5314â€“5317.                                   Notch-induced T-cell acute lymphoblastic leukae-                22(3):189â€“198.
	16.	Subramaniam PS, et al. Targeting nonclassical                  mia. Nat Cell Biol. 2010;12(4):372â€“379.                   	52.	Gil-Ad  et al. Phenothiazines induce apoptosis
      oncogenes therapy T  Cancer Cell. 2012;      	35.	Sablina AA, Hector M, Colpaert N, Hahn WC.                       B16 mouse melanoma cell line attenuate
      21(4):459â€“472.                                                Identification PP2A complexes pathways                   vivo melanoma tumor growth. Oncol Rep. 2006;
	 17.	Zhu HG, Tayeh  Israel L, Castagna M. Different              involved cell transformation. Cancer Res. 2010;              15(1):107â€“112.
      susceptibility lung cell lines inhibitors            70(24):10474â€“10484.                                       	 53.	Sangodkar J, et al. Targeting FOXO1/KLF6 axis
      tumor promotion inducers differentiation.        	 36.	Hahn K, Miranda M, Francis VA, Vendrell J, Zorzano              regulates EGFR signaling treatment response.
      J Biol Regul Homeost Agents. 1991;5(2):52â€“58.                  Teleman AA. PP2A regulatory subunit PP2A-Bâ€²                  J Clin Invest. 2012;122(7):2637â€“2651.
	 18.	Kau TR, et al. chemical genetic screen identifies           counteracts S6K phosphorylation. Cell Metab. 2010;        	 54.	Chiang  et al. Leukemia-associated NOTCH1
      inhibitors regulated nuclear export Fork-             11(5):438â€“444.                                                  alleles weak tumor initiators acceler-
      head transcription factor PTEN-deficient tumor       	 37.	Yeh E, et al. signalling pathway controlling c-Myc            ate K-ras-initiated leukemia. J Clin Invest. 2008;
      cells. Cancer Cell. 2003;4(6):463â€“476.                        degradation impacts oncogenic transformation               118(9):3181â€“3194.
	19.	Choi JH, et al. Potential inhibition PDK1/Akt               human cells. Nat Cell Biol. 2004;6(4):308â€“318.         	55.	Gonzalez-Garcia S, et al. CSL-MAML-dependent
      signaling phenothiazines suppresses cancer cell      	38.	Arnold HK, Sears RC. Protein phosphatase 2A                      Notch1 signaling controls T lineage-specific


654	                                 Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 124â€‚â€‚â€‚Number 2â€‚â€‚â€‚February 2014
                                                                                                                                                      research article

      7R{alpha} gene expression early human             	 61.	Palomero T, et al. Mutational loss PTEN induces     	 68.	Liu Q, et al. FTY720 shows promising vitro       thymopoiesis leukemia. J Exp Med. 2009;                   resistance NOTCH1 inhibition T-cell leuke-             vivo preclinical activity downmodulating
      206(4):779â€“791.                                               mia. Nat Med. 2007;13(10):1203â€“1210.                         Cyclin D1 phospho-Akt mantle cell lym-
	 56.	Zenatti PP, et al. Oncogenic IL7R gain function      	62.	Kridel R, et al. transcriptome sequencing               phoma. Clin Cancer Res. 2010;16(12):3182â€“3192.
      mutations childhood T-cell acute lymphoblastic             reveals recurrent NOTCH1 mutations mantle           	 69.	Langenau DM, et al. Suppression apoptosis       leukemia. Nat Genet. 2011;43(10):932â€“939.                     cell lymphoma. Blood. 2012;119(9):1963â€“1971.                 bcl-2 overexpression lymphoid cells trans-
	 57.	Medyouf H, et al. High-level IGF1R expression        	 63.	Di Ianni M, et al. new genetic lesion B-CLL:          genic zebrafish. Blood. 2005;105(8):3278â€“3285.
      required leukemia-initiating cell activity             NOTCH1 PEST domain mutation. Br J Haematol.            	 70.	Seiler KP, et al. ChemBank: small-molecule screen-
      T supported Notch signaling. J Exp              2009;146(6):689â€“691.                                         ing cheminformatics resource database. Nucleic
      Med. 2011;208(9):1809â€“1822.                             	 64.	Fabbri G, et al. Analysis chronic lymphocytic         Acids Res. 2008;36(Database issue):D351â€“359.
	 58.	Dail M, et al. Mutant Ikzf1, KrasG12D, Notch1             leukemia coding genome: role NOTCH1 muta-           	 71.	Armstrong F, et al. NOTCH key regulator       cooperate T lineage leukemogenesis modu-               tional activation. J Exp Med. 2011;208(7):1389â€“1401.         human T-cell acute leukemia initiating cell activity.
      late responses targeted agents. Proc Natl Acad Sci   	 65.	Puente XS, et al. genome sequencing iden-              Blood. 2009;113(8):1730â€“1740.
      U S  2010;107(11):5106â€“5111.                                tifies recurrent mutations chronic lymphocytic      	72.	Tallarida RJ. Drug synergism: detection
	 59.	Subramanyam D, Krishna S. c-Myc substitutes               leukaemia. Nature. 2011;475(7354):101â€“105.                   applications. J Pharmacol Exp Ther. 2001;
      Notch1-CBF1 functions cooperative transfor-          	66.	Robinson DR, et al. Functionally recurrent rear-              298(3):865â€“872.
      mation papillomavirus oncogenes. Virology.               rangements MAST kinase Notch                	 73.	Groen RW, et al. Reconstructing human hema-
      2006;347(1):191â€“198.                                          gene families breast cancer. Nat Med. 2011;               topoietic niche immunodeficient mice: oppor-
	 60.	Wang H, et al. Genome-wide analysis reveals               17(12):1646â€“1651.                                            tunities studying primary multiple myeloma.
      served divergent features Notch1/RBPJ            	 67.	Liu Q, et al. FTY720 demonstrates promising pre-             Blood. 2012;120(3):e9â€“e16.
      binding human murine T lymphoblas-                     clinical activity chronic lymphocytic leukemia     	74.	Sablina AA, et al. tumor suppressor PP2A
      tic leukemia cells. Proc Natl Acad Sci U S  2011; 